Summary
55 / 100 · Bulios Score
What speaks for it
- Out of every 100 EUR of revenue, 9.4 EUR is left as net profit.
- It could repay all its net debt from 1.9 years of operating profit.
What to watch
- Revenue fell by 12% a year over the last 3 years.
- It cut its dividend by 34% last year.
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 7.8 EUR for 1 EUR of yearly profit. Over the last five years it was 64.5 EUR on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 0.2% a year over 5 years. Over the last 3 years it fell by 12% a year. For the next fiscal year analysts expect revenue to grow by 6.6%.
Growth in detailDoes it make money?
ReasonablyWhere 100 EUR of revenue goes
- Cost of sales 76 EUR
- Research and development 3.2 EUR
- Sales and administration 14 EUR
- Taxes and other -3.0 EUR
- Net profit 9.4 EUR
Net profit, industry median (Chemicals) 4.7 EUR
Out of every 100 EUR of revenue, 9.4 EUR is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 23.9 years of free cash flow. Its debt is larger than its cash. The debt score is high even so.
Financial health in detailDoes it pay a dividend?
High, at risk- Yield
- 4.28%
- Paid out of profit
- 33%
You receive 2.25 € per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 1
- Sell 0
No analyst has published a price target.
50% of the analysts recommend buying.
Analysts in detail